Coherus Oncology (FRA:8C5) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


FRA:8C5 Coherus Oncology Inc FRA:8C5
44 GF Score
Price €1.27
GF Value €0.64
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Coherus Oncology Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Coherus Oncology's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:8C5 vs CNXU, LENZ, FHTX: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Coherus Oncology's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coherus Oncology Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coherus Oncology's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Coherus Oncology's Margin of Safety % (DCF Earnings Based) falls into.


FRA:8C5
44GF Score
Coherus Oncology Inc FRA:8C5
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Coherus Oncology (FRA:8C5) Overvalued in 2026?

Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued. The current stock price of €1.27 is trading 98.3% above its estimated GF Value™ of €0.64. GuruFocus considers Coherus Oncology to be Significantly Overvalued.

Key valuation signals for FRA:8C5:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €0.64 vs. price of €1.27 (98.3% above fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coherus Oncology Business Description

Other Exchanges CHRS:USA
Address 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
44GF Score

Get the complete analysis for FRA:8C5

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.27
Price
€0.64
GF Value